Gilead Sciences
Executive Summary
John Martin on board as VP-R&D from Bristol-Myers Squibb, where he was the director of antiviral chemistry. Foster City, Calif.-based Gilead and Glaxo entered into a five-year $20 mil. R&D cancer development collaboration in July ("The Pink Sheet" July 30, T&G-6).